^
    Back
    Association details:
    Biomarker:CD74 expression
    Cancer:Acute Myelogenous Leukemia
    Drug:STRO-001 (Microtubule inhibitor, CD74-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Blood Adv
    Title:

    Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia

    Published date:
    04/26/2023
    Excerpt:
    We then evaluated the cytotoxicity of STRO-001 in the CD74+ AML cell line (NOMO-1)...Treatment with STRO-001 showed potent, target-dependent cytotoxicity in NOMO-1 cells with half maximal inhibitory concentration (IC-50) of 1.3 nm...These results demonstrate that STRO-001 therapy effectively eradicates CD74+ NOMO-1 leukemia cells in culture and in xenograft models.
    DOI:
    https://doi.org/10.1182/bloodadvances.2022008303
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2021
    Title:

    Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL

    Published date:
    11/04/2021
    Excerpt:
    We evaluated the in vitro cytotoxicity of STRO-001...AML cell lines (MV4;11 and NOMO-1), and ALL cell lines (REH1 and RS4;11) with varied CD74 expression. STRO-001 demonstrates target-specific cytotoxicity against CD74-expressing AML and ALL cell lines...STRO-001 exhibited high potency in CD74 expressing cells, with IC-50s of 41nM (MV4;11), 1.3nM (NOMO-1), 0.7nM (REH-1) and 3nM (RS4;11).
    DOI:
    10.1182/blood-2021-151160